AbCellera Biologics Inc. Business Combination, Contingent Consideration, Liability, Current
AbCellera Biologics Inc. (ABCL) had Business Combination, Contingent Consideration, Liability, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-02-24
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2025-06-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2025-03-31: Business Combination, Contingent Consideration, Liability, Current $8.77M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $8.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $8.09M 10-K · filed 2026-02-24 |
| 2024-09-30 | $20.22M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $20.03M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $51.43M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $50.48M 10-K · filed 2025-02-27 |
| 2023-09-30 | $53.93M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $54.87M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $42.88M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $44.21M 10-K · filed 2024-02-20 |
| 2022-09-30 | $32.53M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $34.25M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $27.50M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $22.93M 10-K · filed 2023-02-21 |
| 2021-09-30 | $12.12M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $11.57M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $13.76M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $13.41M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |